Chetan Vakkalagadda, MD
Medical Oncology · Portland, ORNPI 1447781497
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,003 of the $11,431 with a category attached, or 87.5%. 11 manufacturers reported payments, led by Partner Therapeutics, Inc. at 35.1% of the total. 2025 is the largest year on record at $8,076, more than ten times the $40 reported in 2022.
Across 21 payments — averaging $544.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Partner Therapeutics, Inc.$4K
- Astrazeneca UK Limited$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- AstraZeneca$2K
- Johnson & Johnson$1K
- Jazz Pharmaceuticals Inc.$118
- plus $301 from 5 others
Across 20 payments — averaging $29,654 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$307K
- Janssen Research & Development, LLC$250K
- Amgen$35K
What the payments were for
- Consulting fees$10,00388%
- Travel & lodging$6716%
- Food & beverage$7577%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Partner Therapeutics, Inc. | 10 | $4,009 |
| Astrazeneca UK Limited | 1 | $2,010 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,978 |
| AstraZeneca | 1 | $1,665 |
| Johnson & Johnson | 1 | $1,350 |
| Jazz Pharmaceuticals Inc. | 1 | $118 |
| Gilead | 2 | $108 |
| Regeneron | 1 | $107 |
| Genentech USA, Inc. | 1 | $46 |
| Seagen Inc. | 1 | $25 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,431 in reported general payments places this provider in the 75th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $7,039 |
| Prochlorperazine Maleate | 39 | $943 |
| Dexamethasone | 31 | $362 |
| Oxycodone Hcl | 13 | $173 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Portland
- David PagePortland$238K
- Rachel SanbornPortland$233K
- Matthew TaylorPortland$231K
- Tomasz BeerPortland$102K
- Alison ConlinPortland$85K
- Shivaani KummarPortland$66K
- Stacy LewisPortland$57K
- Hagen KenneckePortland$53K
- Adel KardoshPortland$51K
- Brendan CurtiPortland$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.